PLx Pharma, Inc. (PLXP) News

PLx Pharma, Inc. (PLXP): $2.36

0.05 (+2.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PLXP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 396

in industry

Filter PLXP News Items

PLXP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

PLXP News Highlights

  • PLXP's 30 day story count now stands at 4.
  • Over the past 19 days, the trend for PLXP's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about PLXP are PLX, DRUG and MG.

Latest PLXP News From Around the Web

Below are the latest news stories about PLx Pharma Inc that investors may wish to consider to help them evaluate PLXP as an investment opportunity.

PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update

SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (ref

Yahoo | February 22, 2022

Is PLx Pharma (PLXP) A Worthy Investment?

Summers Value Partners, an investment management firm, published its “Summers Value Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here. The Summers Value Fund LP (“the Fund”) returned 43.4% net for the full year 2021, outpacing the Russell 2000 Index ETF return of 13.7% and the Russell Micro-Cap Index […]

Yahoo | February 21, 2022

PLx Pharma (NASDAQ:PLXP) investors are sitting on a loss of 32% if they invested a year ago

Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. Active...

Yahoo | February 16, 2022

PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness

-- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE® -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the mark

Yahoo | February 3, 2022

PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (

Yahoo | January 19, 2022

A PLx Pharma Inc. (NASDAQ:PLXP) insider increased their holdings by 5.4% last year

Insiders were net buyers of PLx Pharma Inc.'s ( NASDAQ:PLXP ) stock during the past year. That is, insiders bought more...

Yahoo | December 31, 2021

Implied Volatility Surging for Dipexium Pharmaceuticals (PLXP) Stock Options

Investors need to pay close attention to Dipexium Pharmaceuticals (PLXP) stock based on the movements in the options market lately.

Yahoo | December 15, 2021

PLx Pharma gains after Raymond James upgraded on valuation

No summary available.

Seeking Alpha | December 7, 2021

PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021

SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (PLx or the Company) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita OConnor, Chief Financial Officer, are scheduled to present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021.

Intrado Digital Media | November 22, 2021

PLx Pharma Inc. (PLXP): At $10.07, Its Worth Your Attention

PLx Pharma Inc. (NASDAQ:PLXP) price on Friday, November 19, fall -3.36% below its previous days close as a downside momentum from buyers pushed the stocks value to $10.07. A look at the stocks price movement, the close in the last trading session was $10.42, moving within a range at $10.02 and $10.70. The beta value PLx Pharma Inc. (PLXP): At $10.07, Its Worth Your Attention Read More »

Stocks Register | November 20, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5126 seconds.